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ABSTRACT: Protein therapeutics have gained attention recently for
treatment of a myriad of human diseases due to their high potency and
unique mechanisms of action. We present the development of a novel
polymeric thermosponge nanoparticle for eﬃcient delivery of labile
proteins using a solvent-free polymer thermo-expansion mechanism
with clinical potential, capable of eﬀectively delivering a range of
therapeutic proteins in a sustained manner with no loss of bioactivity,
with improved biological half-lives and eﬃcacy in vivo.
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Since the discovery of insulin in the last century, there hasbeen drive to develop improved methods for the delivery of
proteins to patients via pulmonary,1,2 nasal,3,4 and oral
routes.5−7 The main avenues of research in the ﬁeld of
biologics delivery involve either the chemical modiﬁcation of
proteins with sugars,8,9 amino acids,10 or pegylation,11,12 or the
encapsulation, entrapment, or incorporation of proteins within
carriers.5,13−15 Nanotechnology has played a major role in the
design of optimal delivery carriers for biologics with polymeric
nanoparticles being particularly eﬀective platforms for protein
delivery due to the possibility of ﬁne-tuning their overall
biophysicochemical properties16 in addition to their ability to
protect and release proteins in a controlled manner.17−20 Given
that almost a century has passed since the discovery of insulin,
the clinical translation of protein drugs and protein-delivering
nanomedicines has been a very slow process. This is mainly due
to the persistence of major hurdles in the development and
manufacturing of protein-based therapeutics that must be
overcome to achieve clinical translation. Limitations such as
synthetic chemical coupling21 and formulation parameters such
as homogenization, sonication, extrusion, and exposure to
solvents lead to the inactivation of biologics;22−24 thus,
discovery of novel methods of formulation and delivery are
of importance and highly timely.
Here we show the development of a novel two-stage
polymeric thermosponge nanoparticle (TNP) capable of
entrapping a range of proteins in a solvent-free manner, with
sustainable bioactivity postrelease (Figure 1). Our TNPs, which
incorporate poly(D,L-lactide) (PLA) as the core and Pluronic
F127 polymer as the thermosponge shell, are capable of
delivering highly potent proteins such as interleukin 10 (IL-10),
erythropoietin (EPO), insulin, and human growth hormone
(hGH). These were chosen as model proteins because they
contain amino acids that produce positive (IL-10 and EPO) or
negative (insulin and hGH) electrostatic charges. In addition,
these proteins have highly potent therapeutic eﬀects in various
diseases including atherosclerosis (IL-10),25 rheumatoid
arthritis (IL-10),26 anemia (EPO),27 diabetes (insulin),5 and
Turner’s syndrome (hGH).28 The TNPs signiﬁcantly improved
half-life and systemic exposure of important and potent
proteins such as IL-10 and insulin in wild-type mice, as well
as the in vivo eﬃcacy of IL-10. These TNPs may oﬀer
improved therapeutic eﬀects in vivo compared with native
proteins, owing to the integrity of protein bioactivity and long
circulation of proteins loaded inside the hydrophilic sponge
shell layer. Thus, the developed TNPs have promising potential
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for future clinical translation as a solvent-free, scalable, and
biocompatible protein-delivery platform.
Preparation of Thermosponge Nanoparticle Platform.
We developed a nanoparticle platform composed of biocom-
patible and biodegradable polymers (PLA, PLGA, and
Pluronic) already approved by the FDA (and therefore readily
applicable to clinical trials) via a facile single-step nano-
precipitation method. First, the composition ratio of the core
and shell layer was optimized for the preparation of TNPs with
stability and small size (<100 nm), using PLGA or PLA with
carboxy terminals as a core component, and Pluronic F127 as a
shell component. The TNPs were developed in various sizes
with core polymer/shell polymer ratios varying from 1:0 to
1:20. Size and zeta potentials ranged from 151 ± 4 nm, −31.2
± 0.6 mV (in the case of PLA-based TNPs, 1:0) and 137 ± 3
nm, −55.5 ± 3.2 mV (in the case of PLGA-based TNPs, 1:0),
to 51 ± 3 nm, −10.3 ± 0.9 mV (in the case of PLA-based
TNPs, 1:20) and 84 ± 1 nm, −23.5 ± 3.2 mV (in the case of
PLGA-based TNPs, 1:20) (Supporting Information, Figure
S1). Notably, in the case of PLA-based TNPs the NPs were
more stable than PLGA-based TNPs in PBS with 10% FBS, as
well as in a resuspended state after lyophilization, indicating a
Figure 1. Schematic illustration of a thermosponge nanoparticle (TNP) platform. (a) TNP preparation by a one-step nanoprecipitation method. (b)
Solvent-free method of protein-loading into TNPs for eﬃcient delivery of labile therapeutic protein drugs. TNPs can be eﬃciently loaded with
desired proteins in a thermoresponsive manner without organic solvents due to the combination of the thermoresponsive swelling behavior of the
Pluronic shell of TNPs at 4 °C and the electrostatic interactions between the absorbed proteins and the PLA core of TNPs. The positively charged
and negatively charged PLA cores of TNPs were synthesized using PLA-NH2 and PLA-COOH, respectively, and were tested for loading of relevant
therapeutic proteins such as slightly positively charged proteins [IL-10 (isoelectric point (pI) 7.9) EPO (pI 8.3)] and negatively charged proteins
[Insulin (pI 5.3) and hGH (pI 5.2)] in deionized water.
Figure 2. Characterization of TNPs. (a) Hydrodynamic diameters and (b) surface charges of TNPs and therapeutic protein-loaded TNPs. (c)
Representative TEM image of TNPs. The scale bar is 500 nm. Inset is a high-magniﬁcation image with the scale bar representing 50 nm. (d) Swelling
and deswelling behavior of TNPs in response to temperature changes. (e) Loading contents (wt %) of therapeutic proteins (IL-10, EPO, insulin, and
hGH) into negatively charged or positively charged TNPs. (f) In vitro cumulative release patterns of therapeutic proteins from TNPs in PBS buﬀer
at 100 rpm and 37 °C, analyzed by ELISA (mean ± SD, n = 3).
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stronger hydrophobic interaction between the PLA and
Pluronic polymers (Supporting Information, Figure S3). In
addition, the NPs showed high encapsulation eﬃciency (90%)
and loading content (4.3 wt %) of lysozyme as a model protein
with positive charge and controlled-release kinetics up to a
week in PBS as well as PBS (10% FBS), implying that a
suﬃcient amount of protein drug, could be delivered within a
reasonably short period to the target site (Supporting
Information, Figure S4). In the cytotoxicity test, NPs ranging
from 0.1 to 10 mg/mL did not aﬀect the metabolic activity of
RAW 264.7 macrophage cells for both 24 and 72 h incubation
periods (Supporting Information, Figure S5). Therefore, we
determined the optimal formulation to be PLA as a core
material, Pluronic F127 as a thermosponge shell, and a core/
shell ratio of 1:20 for a nanoparticle platform (with a negative
charge or positive charge core) to deliver various therapeutic
proteins with positive charges (IL-10, EPO, etc.) or negative
charges (Insulin, hGH, etc.).
Protein-loaded TNPs via a solvent-free encapsulation
method. TNPs (1:20 ratio), optimized for physicochemical
characteristics and stability, were prepared by the nano-
precipitation method as described above. In the case of the
negatively charged TNPs (PLA-COOH as a core), the
hydrodynamic size and surface charge were 54 ± 1 nm and
−10.2 ± 1.6 mV, respectively, whereas the positively charged
TNPs (PLA-NH2 as a core) were 81 ± 1 nm in size and had a
surface charge of 7.3 ± 2.1 mV (Figure 2a,b). Interestingly,
both TNPs demonstrated similar temperature-responsive
swelling/deswelling Pluronic shell behavior such as change in
size ∼96 nm at 4 °C, ∼54 nm at 25 °C, and ∼35 nm at 37 °C
(in the case of negatively charged TNPs) and ∼141 nm at 4 °C,
∼ 81 nm at 25 °C, and ∼51 nm at 37 °C (in the case of
positively charged TNPs) (Figure 2d). In addition, the
morphological characteristics of TNPs were assessed using
transmission electron microscopy (TEM) after negative
staining (Figure 2c). TEM images indicated a spherical core-
sponge shell structure for the negatively charged NPs, and
similar diameters were obtained with dynamic light scattering.
The positively and negatively charged TNPs showed very
similar results. The core-sponge shell structure is also clearly
visible in the high-magniﬁcation image in the inset of Figure 2c
and easily discriminated when compared with the morphology
of PEG−PLA nanoparticles (Supporting Information, Figure
S6).
Next, therapeutic proteins (both positively charged IL-10 and
EPO and negatively charged insulin and hGH) were
successfully loaded into each type of TNP without organic
solvents, using two driving forces: (1) the electrostatic
interaction between a negatively charged or positively charged
PLA core and slightly positively charged or negatively charged
proteins in deionized water (Figure 2e) and (2) the volume
expansion of the Pluronic shell at low temperature (Figure 2d).
After loading the proteins into TNPs, the unencapsulated
proteins were separated by ultraﬁltration and analyzed for
loading content (∼2.0 wt %) (Figure 2e) and encapsulation
eﬃciency (∼90%). Importantly, the physicochemical parame-
Figure 3. Bioactivity of proteins released from TNPs. (a) Inhibitory eﬀects on reactive oxygen species (ROS) production by IL-10 at various
concentrations (1−100 ng/mL). Intracellular ROS generated from RAW 264.7 macrophage cells by LPS stimulation was measured using a ROS
detection reagent. Bioactivity analysis of the inhibitory eﬀects of native IL-10, released IL-10, and loaded IL-10 on ROS production (b) by
pretreatment and (c) by post-treatment of IL-10 (n = 3, * p < 0.05, # p > 0.05). (d) Relative mRNA expression of TNF-α, IL-12, and sIL-1Ra after
LPS treatment (500 ng/mL) for 4 h, followed by treatment with IL-10 (native IL-10 or released IL-10 at 20 ng/mL) for 2 h at 37 °C (n = 3, # p >
0.05). (e) Western blots were performed to analyze the bioactivity of IL-10 released from TNPs after treatment with IL-10 (native IL-10 or released
IL-10 at 20 ng/mL) for 24 h at 37 °C. #1, control; #2, native IL-10; and #3, released IL-10. (f) Bioactivity analysis of native insulin and released
insulin (10 nM) on the improved proliferation eﬀect of insulin-dose-dependent human breast cancer cell line MCF-7 (n = 3, # p > 0.05).
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ters (size, surface charge, and morphology) of the NPs were not
substantially aﬀected by loading the proteins into the NPs
(protein@TNP), suggesting that the proteins were eﬀectively
shielded (Figure 2a,b). The release proﬁles of the proteins from
the NPs showed similar patterns of sustained release for 4 days
without an initial burst because of the swelling with the
Pluronic leading to entrapment of the proteins as well as the
electrostatic interaction with the PLA core leading to retention
of them (Figure 2f). On the basis of these successful results, we
further investigated the biological integrity of IL-10 and insulin
proteins, as IL-10 has been shown to be a highly potent anti-
inﬂammatory cytokine with potential therapeutic aﬀects in
atherosclerosis treatment,25 and successful insulin delivery is
also a highly important unmet medical need.5
Inhibitory Eﬀect of IL-10 on ROS Production. To
analyze the bioactivity of IL-10 released from the NPs, the
intracellular reactive oxygen species (ROS) generated from
LPS-stimulated RAW 264.7 macrophages was measured with a
widely used ROS detection kit (H2DCFDA).29,30 Before the
inhibitory eﬀect of IL-10 on the ROS formation was checked,
LPS treatment conditions for cell stimulation were optimized
by varying the concentration of LPS (100, 300, and 500 ng/
mL) and incubation time (4 and 24 h). Overproduction of
ROS increased with stimulation time of LPS with macro-
phages,31 whereas the LPS concentration (ranging from 100 to
500 ng/mL) did aﬀect ROS generation but not in a dose-
dependent manner, implying that LPS with 100 ng/mL was
enough to induce ROS (Supporting Information, Figure S7a).
The inhibitory eﬀect of IL-10 on ROS production in LPS-
induced macrophages was investigated using various concen-
trations (1−100 ng/mL) of IL-10 and 100 ng/mL of LPS
(Figure 3a). The dose-dependent inhibition eﬀect of IL-10 on
ROS production was observed more clearly through the
pretreatment of cells with IL-10 for 24 h and stimulation with
LPS for 24 h, compared to the shorter induction time of cells
pretreated with IL-10 and LPS.32
To assess the biological integrity/activity of IL-10 released
from NPs, we evaluated native IL-10, IL-10 released from NPs
at 48 h, and IL-10-loaded NPs at 50 ng/mL of IL-10 and 100
ng/mL of LPS. In the case of pretreatment of cells with IL-10
(i.e., the prophylactic concept), there was almost no statistical
diﬀerence between the released IL-10 and native IL-10 (# p >
0.05) (Figure 3b). Interestingly, in the case of IL-10−loaded
NPs, slightly lower activity than the native and released IL-10
indicated that IL-10 was still inside the NPs based on statistical
analysis (* p < 0.05), suggesting both eﬃcient loading and
controlled release. More importantly, in the case of post-
treatment of cells with IL-10 (i.e., the therapeutic concept), the
inhibitory eﬀect on ROS production was enhanced with all
samples; most notably, the bioactivity of released IL-10 was
similar to that of the native protein (Figure 3c), indicating that
it was maintained during both loading and release.
Bioactivity Analysis of IL-10 Using qPCR and Western
Blot. To determine whether the IL-10 released from NPs
inhibits proinﬂammatory cytokines produced by inﬂammatory
responses, the relative gene expression levels of TNF-α and IL-
12 were compared with the native IL-10 through qPCR (Figure
3d). Expression was dramatically increased after LPS
stimulation and the released IL-10 reduced the expression of
cytokines (ca. 2.5-fold), suggesting that the released IL-10 not
only retains bioactivity, but also functions as an anti-
inﬂammatory cytokine, with results similar to native IL-10. In
addition, IL-10 treatment increased sIL-1Ra promoter activity
by 1.5-fold compared to LPS alone, and the released IL-10 had
eﬀects identical to those of the native protein, consistent with
the unique response of IL-10 to the gene expression of the
secretory interleukin (IL)-1 receptor antagonist (sIL-1Ra) for
which previous studies demonstrate the potential to treat
metastatic cancers.33 The gene expression of several cytokines
analyzed in this study suggests that the bioactivity of IL-10
released from the NPs was successfully maintained inside the
hydrophilic shell.
Western blots were also employed to determine whether the
bioactivity of released IL-10 is well maintained. Because IL-10
has been known to signal via the activation of the signal
transducer and activator of transcription 3 (STAT3), which is a
key mediator of the inﬂammatory response of macrophages and
other immune cell types,34 the levels of STAT3 and
phosphorylated STAT3 (P-STAT3 at Tyr705) were measured.
Compared to the control group, the total levels of STAT3 were
slightly increased by IL-10 treatment, using β-Actin as a
reference protein (Figure 3e). Moreover, the clear band of P-
STAT3 was observed in the native IL-10 group, indicating the
activation of STAT3 by IL-10 treatment. The levels of STAT3
and P-STAT3 in the native IL-10 and released IL-10 groups
(respectively) were almost identical, suggesting that IL-10
maintained biological integrity throughout the loading process
and after release.
Bioactivity Analysis of Insulin Using MCF-7 Cells. The
bioactivity of insulin released from TNPs was analyzed via
insulin-dependent proliferation of MCF-7, as reported
previously.35 It was conﬁrmed that the proliferation of MCF-
7 cells was insulin dose-dependent from 1 to 500 nM
(Supporting Information, Figure S8). We compared the
Figure 4. Pharmacokinetics of protein-loaded TNPs. Changes in serum protein levels in mice after intravenous administration of (a) IL-10 and IL-
10−loaded TNP, and (b) insulin and insulin−loaded TNP. The serum concentrations of proteins were measured at several time points using ELISA
kits (mean ± SEM, n = 3).
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enhancement in cell growth (over the control group) produced
by native insulin and released insulin (6 and 48 h postrelease)
at 10 nM concentration in serum-free medium (Figure 3f). As
expected, the released insulin produced almost the same
increase in cellular metabolic activity as native insulin (no
statistical diﬀerences, p > 0.05), indicating that the bioactivity of
proteins released from TNPs was well maintained. Therefore,
based on the results of ROS, qPCR, Western blot, and protein-
dependent cell proliferation assay, the newly developed
nanoparticle platforms (negatively charged and positively
charged TNPs) successfully preserve the bioactivity of loaded
proteins.
Pharmacokinetics of Protein-Loaded TNPs. Protein-
loaded TNPs [IL-10@TNPs (100 μg IL-10/kg) and Insulin@
TNPs (1 U Insulin/kg)] were administered intravenously to
mice, and blood samples were collected at diﬀerent time points
to analyze the serum concentration of proteins (Figure 4). The
mean pharmacokinetic parameters of the proteins were assessed
by noncompartmental analysis (Table 1). After intravenous (iv)
administration of IL-10 alone, the serum IL-10 concentration
rapidly decreased until the 8 h point, whereas the concentration
was maintained up to 24 h when using TNPs (Figure 4a),
increasing the area under the serum concentration−time curve
(AUC) 1.9-fold (from 50.52 to 97.73 ng·hr/ml) (Table 1a). In
addition, IL-10−loaded TNPs reduced the clearance 1.9-fold
(from 1979.57 to 1023.18 mL·hr-1·kg−1) and improved the
half-life 5.9-fold (from 0.25 to 1.48 h) compared with IL-10
alone. Similar results were obtained when insulin-loaded TNPs
were injected into mice (Figure 4b). The insulin-loaded TNPs
produced a remarkable increase in systemic exposure (30.9-
fold, from 25.97 to 804.99 μU·hr/ml) compared with the
insulin-alone group (Table 1b). The group using TNPs also
showed signiﬁcantly reduced clearance (31-fold) and prolonged
half-life of insulin (1.6-fold). Our results demonstrate that the
TNP platform enhances systemic exposure, reduces clearance,
and improves half-life of therapeutic proteins, suggesting that
TNPs could become standard tools for eﬃcient delivery of
proteins for in vivo biomedical applications.
In vivo eﬃcacy of protein-loaded TNPs. In order to
determine whether TNPs are an eﬃcient delivery platform for
protein drugs in vivo, mice were treated systemically with
saline, TNPs, IL-10 (100 μg/kg), or IL-10-loaded TNPs (100
μg IL-10/kg). At 2 h postinjection, DNFB was then applied
topically to the dorsal and ventral aspects of ear skin, and the
ensuing inﬂammatory response was assessed based on the
change in ear swelling and the number of the myeloid cells that
inﬁltrated the ear tissue (Figure 5).
It has been shown that IL-10 is capable of reducing
inﬂammation in DNFB-induced allergic contact dermatitis
(ACD).36 As shown in Figure 5a, although the administration
of IL-10 resulted in a reduction of ear swelling compared to the
saline-treated control, IL-10-loaded TNPs (IL-10@TNPs)
reduced ear swelling much more than IL-10 alone. In addition,
mice treated with IL-10@TNPs had less edema and myeloid
inﬁltration than mice injected with IL-10 alone (Figure 5b) and
showed greater reduction of neutrophil numbers than the saline
group (Figure 5c). The TNPs alone did not elicit any anti-
inﬂammatory eﬀect, indicating that the anti-inﬂammatory
actions of IL-10@TNPs was due to IL-10, not the polymeric
composition of the TNPs. Taken together, the ﬁndings above
suggest that TNPs are a promising nanoplatform for protein
drug delivery, enhancing both the in vivo half-life and eﬃcacy
of protein drugs.
Therapeutic proteins (monoclonal antibodies, growth
hormones, cytokines, erythropoietin, insulin, interferons,
colony-stimulating factors, blood factors, and so forth) have
attracted much attention for their great potential in the
treatment of speciﬁc target diseases.37−39 It is widely believed
that surface modiﬁcation or addition of a delivery carrier to
native proteins could dramatically improve their biological
activity, overcoming such limitations as short half-life (reduced
activity), instability (denaturation or aggregation), and
immunogenicity.
Many carrier systems have been developed and evaluated in
preclinical and clinical trials. In our group, Pridgen et al.
developed Fc-targeted PEG−PLA nanoparticles for oral
delivery of insulin and demonstrated signiﬁcant biological
activity (prolonged glucose suppression) in mice.5 Johnson et
al. reported that hGH-loaded PLGA formulations maintained
hGH serum concentrations for more than a month after a
single subcutaneous (sc) injection in rhesus monkeys.40 The
pharmacokinetics of insulin was improved using PEG-
conjugated liposomes as a delivery carrier, doubling blood
circulation time.41 Dramatic results were also obtained with
recombinant IL-2 incorporated into liposome systems and
injected sc into mice, increasing plasma circulation time 8-fold
compared to native IL-2.42 In addition, in an eﬀort to slow the
rapid clearance of IL-10 in vivo Hamsell et al. reported the
eﬀect of PEGylation of IL-10 on the pharmacokinetics and
biodistribution of this protein, which resulted in a 2.7-fold
increase in systemic half-life.43 However, though the PEGylated
IL-10 showed prolonged blood circulation in vivo, PEGylation
may reduce the bioactivity of IL-10 via lowered binding aﬃnity
or structural deformation. While polymeric and liposome
formulations have been shown to enhance the pharmacoki-
netics of native proteins in vivo, reported loading amounts (0.5
wt %) were not very high, and organic solvents were necessary
in certain formulations.5
Other nanotechnologies employed for protein delivery
include polyglutamate-vitamin E nanogels, and other poly-
saccharide NPs based on chitosan building blocks.44,45
Table 1. Pharmacokinetic Parametersa
a
parameter IL-10 IL-10@TNP
dose (μg/kg) 100 100
clearance (ml·hr−1·kg−1) 1979.57 1023.18
Vss (ml/kg) 707.27 2179.42
AUC0‑∞ (ng·hr/ml) 50.52 97.73
MRT (hr) 0.36 2.13
T1/2 terminal (hr) 0.25 1.48
b
parameter insulin insulin@TNP
dose (U/kg) 1 1
clearance (ml·hr−1·kg−1) 38512.48 1242.25
Vss (ml/kg) 10159.47 531.18
AUC0‑∞ (μU·hr/ml) 25.97 804.99
MRT (hr) 0.26 0.43
T1/2 terminal (hr) 0.18 0.30
aPharmacokinetic parameters of (a) IL-10 and IL-10−loaded TNP
and (b) insulin and insulin-loaded TNP administered intravenously to
mice. The parameters were analyzed using a noncompartmental
model. AUC, area under the concentration−time curve; Vss, volume
of distribution at steady state; MRT, mean residence time.
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However, the chitosan nanoparticles also showed highly
increased size range of 200 to 580 nm as well as noncontrolled
initial burst eﬀect of protein drugs.45 Although these methods
also do not use solvents in their preparation, an advantage of
the developed TNPs over these previously developed systems
in addition to also being solvent-free is that our nanoplatform is
applicable to the delivery of a range of proteins with diﬀerent
sizes and charges. Furthermore, the preparation of protein-
loaded TNPs is relatively facile and does not require
complicated set-ups and relies on simple mixing and electro-
static interactions.
Here we demonstrate a nanoparticle platform with a simple
solvent-free encapsulation method. The TNPs showed strong
structural stability in a model serum buﬀer and in resuspension
conditions without the need for any cryo-protectants,
suggesting that this platform would be amenable to clinical
translation. On the basis of the results of ROS, qPCR, Western
blot, and protein-dependent cell proliferation assay in vitro, it is
clear that the bioactivity of proteins (e.g., IL-10, insulin) was
well preserved inside NPs. More importantly, the TNPs
signiﬁcantly increased the half-life and systemic exposure of
model therapeutic proteins such as IL-10 (t1/2 5.9-fold) and
insulin (t1/2 1.6-fold) in mice without chemical modiﬁcations.
In addition to increasing the in vivo eﬃcacy of IL-10, these
ﬁndings highlight the potential of TNPs as a general solvent-
free delivery nanoplatform for the eﬃcient delivery of many
other therapeutic proteins
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